No profile data available.
Amneal Pharmaceuticals, Inc. (AMRX) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Bridgewater, United States, with about 8,700 full-time employees.
It reported revenue of $3.02 billion for fiscal year 2025, up 8.0% from fiscal year 2024, and net income of $72.06 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $796.20 million, up 9.9% from a year before. Its largest business segment, Affordable Medicines, brought in 58% of segment revenue in fiscal year 2025. Its market capitalization was $6.93 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Amneal Pharmaceuticals reported $3.02 billion in revenue for fiscal year 2025, up 8.0% from $2.79 billion in fiscal year 2024. In Q2 2026 revenue was $796.20 million.
Affordable Medicines, with $1.75 billion or 58% of segment revenue in fiscal year 2025. Next: Avkare (25%) and Specialty (18%).
$6.93 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Viatris Inc. (VTRS), Dr. Reddy's Laboratories Limited (RDY), Ionis Pharmaceuticals, Inc. (IONS), Ligand Pharmaceuticals Incorporated (LGND).